Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial.

Campochiaro PA, Marcus DM, Awh CC, Regillo C, Adamis AP, Bantseev V, Chiang Y, Ehrlich JS, Erickson S, Hanley WD, Horvath J, Maass KF, Singh N, Tang F, Barteselli G.

Ophthalmology. 2019 Aug;126(8):1141-1154. doi: 10.1016/j.ophtha.2019.03.036. Epub 2019 Apr 1.

2.

Deep Learning Predicts OCT Measures of Diabetic Macular Thickening From Color Fundus Photographs.

Arcadu F, Benmansour F, Maunz A, Michon J, Haskova Z, McClintock D, Adamis AP, Willis JR, Prunotto M.

Invest Ophthalmol Vis Sci. 2019 Mar 1;60(4):852-857. doi: 10.1167/iovs.18-25634.

PMID:
30821810
3.

Ten years of anti-vascular endothelial growth factor therapy.

Ferrara N, Adamis AP.

Nat Rev Drug Discov. 2016 Jun;15(6):385-403. doi: 10.1038/nrd.2015.17. Epub 2016 Jan 18.

4.

Ocular Angiogenesis: Vascular Endothelial Growth Factor and Other Factors.

Rubio RG, Adamis AP.

Dev Ophthalmol. 2016;55:28-37. doi: 10.1159/000431129. Epub 2015 Oct 26. Review.

PMID:
26502333
5.

Targeting the Effect of VEGF in Diabetic Macular Edema.

Adamis AP, Ehrlich J, Fung A.

N Engl J Med. 2015 Jul 30;373(5):480-1. doi: 10.1056/NEJMc1505684. No abstract available. Erratum in: N Engl J Med. 2015 Sep 3;373(10):982.

PMID:
26222568
6.

Spontaneous CNV in a novel mutant mouse is associated with early VEGF-A-driven angiogenesis and late-stage focal edema, neural cell loss, and dysfunction.

Nagai N, Lundh von Leithner P, Izumi-Nagai K, Hosking B, Chang B, Hurd R, Adamson P, Adamis AP, Foxton RH, Ng YS, Shima DT.

Invest Ophthalmol Vis Sci. 2014 May 20;55(6):3709-19. doi: 10.1167/iovs.14-13989.

7.

Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.

Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, Schlottmann PG, Rundle AC, Zhang J, Rubio RG, Adamis AP, Ehrlich JS, Hopkins JJ; RIDE and RISE Research Group.

Ophthalmology. 2013 Oct;120(10):2013-22. doi: 10.1016/j.ophtha.2013.02.034. Epub 2013 May 22.

8.

Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.

Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY.

Ophthalmology. 2011 Aug;118(8):1594-602. doi: 10.1016/j.ophtha.2011.02.022.

PMID:
21684606
9.

The case for complement and inflammation in AMD: open questions.

Karagianni N, Adamis AP.

Adv Exp Med Biol. 2010;703:1-7. doi: 10.1007/978-1-4419-5635-4_1. Review.

PMID:
20711703
10.

Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization.

Zahn G, Vossmeyer D, Stragies R, Wills M, Wong CG, Löffler KU, Adamis AP, Knolle J.

Arch Ophthalmol. 2009 Oct;127(10):1329-35. doi: 10.1001/archophthalmol.2009.265.

PMID:
19822850
11.

Assessment of the integrin alpha5beta1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachment.

Zahn G, Volk K, Lewis GP, Vossmeyer D, Stragies R, Heier JS, Daniel PE Jr, Adamis AP, Chapin EA, Fisher SK, Holz FG, Löffler KU, Knolle J.

Invest Ophthalmol Vis Sci. 2010 Feb;51(2):1028-35. doi: 10.1167/iovs.09-3575. Epub 2009 Oct 8.

PMID:
19815730
12.

The rationale for drug combinations in age-related macular degeneration.

Adamis AP.

Retina. 2009 Jun;29(6 Suppl):S42-4. doi: 10.1097/IAE.0b013e3181ad2500.

PMID:
19553800
13.

Judah Folkman.

Adamis AP, Miller JW.

Semin Ophthalmol. 2009 May-Jun;24(3):128-9. doi: 10.1080/08820530902800116. No abstract available.

PMID:
19437346
14.

Pegaptanib sodium for macular edema secondary to central retinal vein occlusion.

Wroblewski JJ, Wells JA 3rd, Adamis AP, Buggage RR, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Altaweel MM; Pegaptanib in Central Retinal Vein Occlusion Study Group.

Arch Ophthalmol. 2009 Apr;127(4):374-80. doi: 10.1001/archophthalmol.2009.14.

PMID:
19365011
15.

Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.

Singerman LJ, Masonson H, Patel M, Adamis AP, Buggage R, Cunningham E, Goldbaum M, Katz B, Guyer D.

Br J Ophthalmol. 2008 Dec;92(12):1606-11. doi: 10.1136/bjo.2007.132597. Epub 2008 Jul 9.

16.

Immunological mechanisms in the pathogenesis of diabetic retinopathy.

Adamis AP, Berman AJ.

Semin Immunopathol. 2008 Apr;30(2):65-84. doi: 10.1007/s00281-008-0111-x. Epub 2008 Mar 14. Review.

PMID:
18340447
17.

Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization.

Ju M, Mailhos C, Bradley J, Dowie T, Ganley M, Cook G, Calias P, Lange N, Adamis AP, Shima DT, Robinson GS.

Invest Ophthalmol Vis Sci. 2008 Feb;49(2):662-70. doi: 10.1167/iovs.07-0195.

PMID:
18235012
18.

Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity.

Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ, Shah SN, Adamis AP.

Value Health. 2008 Jul-Aug;11(4):563-74. doi: 10.1111/j.1524-4733.2007.00283.x. Epub 2007 Dec 17.

19.

Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.

Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT.

Am J Pathol. 2007 Jul;171(1):53-67.

20.

Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.

Macugen AMD Study Group, Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP.

Ophthalmology. 2007 Sep;114(9):1702-12. Epub 2007 May 23.

PMID:
17509689
21.

Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice.

Zhong L, Bradley J, Schubert W, Ahmed E, Adamis AP, Shima DT, Robinson GS, Ng YS.

Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1212-8.

PMID:
17325165
22.

Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products.

Kaji Y, Usui T, Ishida S, Yamashiro K, Moore TC, Moore J, Yamamoto Y, Yamamoto H, Adamis AP.

Invest Ophthalmol Vis Sci. 2007 Feb;48(2):858-65.

PMID:
17251488
23.

Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy.

Starita C, Patel M, Katz B, Adamis AP.

Dev Ophthalmol. 2007;39:122-148. doi: 10.1159/000098504. Review.

PMID:
17245083
24.

Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases.

Ng EW, Adamis AP.

Ann N Y Acad Sci. 2006 Oct;1082:151-71. Review.

PMID:
17145936
25.

Inhibitory effect of an antibody to cryptic collagen type IV epitopes on choroidal neovascularization.

Jo N, Ju M, Nishijima K, Robinson GS, Adamis AP, Shima DT, Mailhos C.

Mol Vis. 2006 Oct 26;12:1243-9.

26.

Molecular biology of choroidal neovascularization.

Lu M, Adamis AP.

Ophthalmol Clin North Am. 2006 Sep;19(3):323-34. Review.

PMID:
16935207
27.

Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.

VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Patel M.

Ophthalmology. 2006 Sep;113(9):1508.e1-25. Epub 2006 Jul 7.

PMID:
16828500
28.

Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California).

Lutty GA, Chan-Ling T, Phelps DL, Adamis AP, Berns KI, Chan CK, Cole CH, D'Amore PA, Das A, Deng WT, Dobson V, Flynn JT, Friedlander M, Fulton A, Good WV, Grant MB, Hansen R, Hauswirth WW, Hardy RJ, Hinton DR, Hughes S, McLeod DS, Palmer EA, Patz A, Penn JS, Raisler BJ, Repka MX, Saint-Geniez M, Shaw LC, Shima DT, Smith BT, Smith LE, Tahija SG, Tasman W, Trese MT.

Mol Vis. 2006 May 23;12:532-80.

29.

Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization.

Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K, Robinson GS, Adamis AP, Shima DT.

Am J Pathol. 2006 Jun;168(6):2036-53.

30.

Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.

VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, Guyer DR, Katz B.

Ophthalmology. 2006 Jun;113(6):992-1001.e6. Epub 2006 Apr 27.

PMID:
16647134
31.

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.

Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP.

Nat Rev Drug Discov. 2006 Feb;5(2):123-32. Review.

PMID:
16518379
32.

Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals.

Adamis AP, Altaweel M, Bressler NM, Cunningham ET Jr, Davis MD, Goldbaum M, Gonzales C, Guyer DR, Barrett K, Patel M; Macugen Diabetic Retinopathy Study Group.

Ophthalmology. 2006 Jan;113(1):23-8. Epub 2005 Dec 15.

PMID:
16343627
33.

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.

Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD; Macugen Diabetic Retinopathy Study Group.

Ophthalmology. 2005 Oct;112(10):1747-57.

PMID:
16154196
34.

Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration.

Ng EW, Adamis AP.

Can J Ophthalmol. 2005 Jun;40(3):352-68. Review.

PMID:
15947805
35.

The role of vascular endothelial growth factor in ocular health and disease.

Adamis AP, Shima DT.

Retina. 2005 Feb-Mar;25(2):111-8. Review.

PMID:
15689799
36.

Pegaptanib for neovascular age-related macular degeneration.

Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group.

N Engl J Med. 2004 Dec 30;351(27):2805-16.

37.

Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy.

Poulaki V, Joussen AM, Mitsiades N, Mitsiades CS, Iliaki EF, Adamis AP.

Am J Pathol. 2004 Aug;165(2):457-69.

38.

A central role for inflammation in the pathogenesis of diabetic retinopathy.

Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP.

FASEB J. 2004 Sep;18(12):1450-2. Epub 2004 Jul 1.

PMID:
15231732
39.

Ocular delivery of angiostatic agents.

Lu M, Adamis AP.

Int Ophthalmol Clin. 2004 Summer;44(3):41-51. Review. No abstract available.

PMID:
15211176
40.

VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2.

Usui T, Ishida S, Yamashiro K, Kaji Y, Poulaki V, Moore J, Moore T, Amano S, Horikawa Y, Dartt D, Golding M, Shima DT, Adamis AP.

Invest Ophthalmol Vis Sci. 2004 Feb;45(2):368-74.

PMID:
14744874
41.

Angiogenesis and ophthalmic disease.

Adamis AP, Aiello LP, D'Amato RA.

Angiogenesis. 1999;3(1):9-14.

PMID:
14517440
42.

The role of advanced glycation end products in retinal microvascular leukostasis.

Moore TC, Moore JE, Kaji Y, Frizzell N, Usui T, Poulaki V, Campbell IL, Stitt AW, Gardiner TA, Archer DB, Adamis AP.

Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4457-64.

PMID:
14507893
43.

VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization.

Ishida S, Usui T, Yamashiro K, Kaji Y, Amano S, Ogura Y, Hida T, Oguchi Y, Ambati J, Miller JW, Gragoudas ES, Ng YS, D'Amore PA, Shima DT, Adamis AP.

J Exp Med. 2003 Aug 4;198(3):483-9.

44.

Inhibition of corneal neovascularization by genetic ablation of CCR2.

Ambati BK, Joussen AM, Kuziel WA, Adamis AP, Ambati J.

Cornea. 2003 Jul;22(5):465-7.

PMID:
12827053
45.

Platelets accumulate in the diabetic retinal vasculature following endothelial death and suppress blood-retinal barrier breakdown.

Yamashiro K, Tsujikawa A, Ishida S, Usui T, Kaji Y, Honda Y, Ogura Y, Adamis AP.

Am J Pathol. 2003 Jul;163(1):253-9.

46.

Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization.

Sakurai E, Taguchi H, Anand A, Ambati BK, Gragoudas ES, Miller JW, Adamis AP, Ambati J.

Invest Ophthalmol Vis Sci. 2003 Jun;44(6):2743-9.

PMID:
12766082
47.

Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies.

Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP.

Surv Ophthalmol. 2003 May-Jun;48(3):257-93. Review.

PMID:
12745003
48.

Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease.

Ishida S, Yamashiro K, Usui T, Kaji Y, Ogura Y, Hida T, Honda Y, Oguchi Y, Adamis AP.

Nat Med. 2003 Jun;9(6):781-8. Epub 2003 May 5.

PMID:
12730690
49.

VEGF164 is proinflammatory in the diabetic retina.

Ishida S, Usui T, Yamashiro K, Kaji Y, Ahmed E, Carrasquillo KG, Amano S, Hida T, Oguchi Y, Adamis AP.

Invest Ophthalmol Vis Sci. 2003 May;44(5):2155-62.

PMID:
12714656
50.

Endothelial-directed hepatic regeneration after partial hepatectomy.

Greene AK, Wiener S, Puder M, Yoshida A, Shi B, Perez-Atayde AR, Efstathiou JA, Holmgren L, Adamis AP, Rupnick M, Folkman J, O'Reilly MS.

Ann Surg. 2003 Apr;237(4):530-5.

Supplemental Content

Loading ...
Support Center